Podcast appearances and mentions of jesus san miguel

Join us as we talk with renown myeloma expert Dr. Jesus San Miguel of the University Hospital of Salamanca about high risk myeloma, recent findings of the International Myeloma Working Group and his work on minimal residual disease.

Interview with Jesus San Miguel, from Spain. Prof. San Miguel discusses the topic 'Multiple Myeloma New Treatments'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Jesus San Miguel, from Spain. Prof. San Miguel discusses the topic 'Multiple Myeloma New Treatments'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Dr Pieter Sonneveld, Prof Michele Cavo, Dr Jesus San Miguel and Dr Meletios Dimopoulos discuss the highlights from the Multiple Myeloma Debate in Copenhagen The panel discusses the most recent data presented on: Current and emerging treatment paradigms: Choice between sequential or combination therapy for MM The role of new therapies such as pomalidomide Role of carfilzomib plus melphalan and prednisone as the upfront therapy of elderly patients with MM New agents, such as MLN-9708, (an oral proteasome inhibitor), and daratumumab (an anti-CD38 monoclonal antibody) Relapsed MM: Defining the correct sequence of novel agents in the treatment of relapsed MM Recognising and responding to resistance in relapsed MM Primary refractory or multiply-relapsed MM: What are our options? Transplantation: The role of allotransplant in the era of novel therapies How salvage autologous stem cell transplantation (ASCT) can achieve sustained disease control in recurrent MM Optimal pre-transplant therapy Best practice for post transplantation consolidation and maintenance therapy This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).

Jesus San Miguel discusses a phase 3 trial comparing pomalidomide plus low-dose dexamethasone with high-dose dexamethasone in patients with multiple myeloma.

Prof Jesus San Miguel talks with ecancer at the 18th EHA Congress about the MM-003 trial. MM-003 is a large, multi-centre phase III study that assessed the efficacy and safety of a new drug, pomalidomide (POM) in combination with low-dose dexamethasone (POM LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage disease which have previously failed lenalidomide and bortezomib.

The use of novel agents bortezomib, lenalidomide and thalidomide in Asian patients is discussed. Bortezomib is used as induction therapy and lenalidomide and thalidomide are reserved for relapsed or refractory patients in Japan. Rare reports of complications with these agents have been reported, However these are not believed to be treatment related. The increased incidence of cancer in survivors of the atomic bomb during World War II has been addressed at IMW. Results from the Life Span Study investigating radiation effects on leukaemia, lymphoma and MM incidence in atomic bomb survivors were presented at this year's IMW meeting. This study found that the radiation exposure associated with this may be a possible predisposing factor for MGUS. However, the incidence of multiple myeloma appears to be the same as Western populations. Overall, the incidence of MM appears to be lower in the Asian population, but higher rates have been noted in Vietnamese patients. A number of clinical studies are ongoing covering the use of novel therapies, autologous stem cell transplant and maintenance therapy.

George Canellos, What’s hot from the ASH Plenary Session. Maria-Victoria Mateos of Salamanca University in Spain on melphalan as the better partner drug for bortezomib in multiple myeloma; Commentary Dr. Canellos and Jesus San-Miguel, also of Salamanca, and Richard Van Etten of Tufts University. Steven Devine of Ohio State University on T-cell depletion to avoid GVHD in AML; commentary from Dr. Canellos and Armand Keating of the University of Toronto.